Sanofi terminates losmapimod deal; Fulcrum loses up to $975M in milestones

Fulcrum Therapeutics, Inc.

Sanofi terminated for convenience the May 2024 collaboration for losmapimod (FSHD) effective April 17, 2025.
Fulcrum received $80M upfront but forfeits all remaining milestones (up to $975M) and tiered royalties.
Fulcrum no longer entitled to global development cost reimbursement; Phase 3 trial obligations continue until termination.
After termination, Fulcrum retains full rights to losmapimod but loses ex-U.S. partner and future payments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.